We have previously reported the identification of a novel 17 kDa truncated isoform of the cyclin D2 activated in 13% of the leukemias induced by the Graffi murine leukemia retrovirus. Retroviral integration in the Gris1 locus causes an alternative splicing of the mouse cyclin D2 gene and expression of a truncated protein of 159 amino acids that is detected at high levels in the Gris1 tumors and also in normal mouse tissues mainly the brain and ovaries. A truncated form of the cyclin D2 was also found in human. We show here that both mouse-and humantruncated cyclin D2 are able to transform primary mouse embryo fibroblasts (MEF) when co-expressed with an activated Ras protein. The truncated cyclin D2 localizes only to the cytoplasm of transfected cells. It has retained the ability to interact with cyclin-dependent kinases (CDKs), although it is a poor catalyst of pRb phosphorylation. Interestingly, the presence of a similar, alternatively spliced cyclin D2 mRNA was also detected in some human brain tumors.
Introduction
Slow-transforming murine retroviruses can induce leukemia in their host by insertional mutation of cellular proto-oncogenes or tumor suppressor genes. Following the retroviral integration, cellular genes may become aberrantly expressed through activation by viral promoter or enhancer sequences. The abnormal expression of a certain proto-oncogene may then provide a growth advantage to the target cell and contribute to malignant transformation. During the past years an important number of critical cancer genes have been identified in these leukemias by proviral tagging. We have recently characterized Gris1 as a novel common integration site in 13% of Graffi murine retrovirus-induced leukemias (Denicourt et al., 2002) . This novel locus was located on mouse chromosome 6, 75-85 kbp upstream of the cyclin D2 gene. Integrations in Gris1 were shown to activate the expression of the 6.5 kb major transcript of the cyclin D2 gene (CCND2) and also a smaller 1.1 kb transcript that we have shown to represent an alternative transcript encoding a 17 kDa truncated cyclin D2 protein. The protein is detected at high level in the Gris1 tumors and also in smaller quantities in normal tissue mainly in the brain and ovaries (Denicourt et al., 2002) . We also have reported the existence of several expressed sequence tags (ESTs) in the databases encoding a similar truncated cyclin D2 in humans. Moreover, such a transcript was also reported in Xenopus laevis cloned from an ovary cDNA library (Taı¨eb and Jessus, 1996) .
Cyclin D2 is a G 1 cyclin that belongs to the family of three closely related D-type cyclins, namely, D1, D2 and D3. These cyclins have been identified as positive regulators of the cell cycle and have a well-established role in the progression through the G 1 phase of the cell cycle. D-type cyclins assemble with their cyclin-dependent kinase (CDK) partners CDK4 and CDK6 to phosphorylate target proteins such as pRb (reviewed in Sherr and Roberts, 1999; Ortega et al., 2002) . Mitogenic signaling ultimately leads to the upregulated expression of D-type cyclins as well as their kinase-associated activity.
Cyclin D2 is a well-defined human proto-oncogene and, when illegitimately activated or overexpressed, it can contribute to cellular transformation (reviewed in Malumbres and Barbacid, 2001) . Indeed, deregulated expression of the cyclin D2 gene has been reported for the first time in murine leukemia virus-induced T-cell leukemias by the identification of the common viral integration site vin1 (Tremblay et al., 1992; Hanna et al., 1993) . In collaboration with an activated Ras (H-RasV12), overexpressed cyclin D2 can transform primary rat embryo fibroblasts (REF) (Kerkhoff and Ziff, 1995) . In human, overexpression of cyclin D2 is associated with different types of lymphoid malignancy, testicular carcinoma and ovarian cancer (Sicinski et al., 1996; Bartkova et al., 1999; Teramoto et al., 1999) .
In this article, we present evidence that the overexpression of the truncated cyclin D2 can transform primary MEF in conjunction with activated Ras. We also present evidence for a human homolog transcript of a truncated cyclin D2 that is overexpressed in some types of primary human brain tumors. As opposed to the subcellular localization of the cyclin D2 protein, this truncated cyclin D2 was never observed in the nucleus of NIH/3T3 fibroblasts but was predominantly localized to the cytoplasm. Despite the fact that this truncated cyclin represents half of the full-length cyclin D2, this isoform still retains the ability to interact with CDK4, but the complex is unable to phosphorylate its target pRb.
Results
Ectopic expression of the truncated cyclin D2 and activated Ras causes transformation of primary MEF Since the truncated cyclin D2 transcript was found overexpressed in the leukemias induced by Graffi retrovirus, we hypothesized that the protein could probably function as an oncogene. MEF were transfected with a truncated cyclin D2 expressing construct and with an activated H-Ras to determine if it was able to transform in vitro. As controls, MEF were also transfected with H-Ras alone, H-Ras þ c-Myc and H-Ras þ cyclin D2. The truncated cyclin D2 was not able to induce transformation alone or with c-Myc (not shown and Figure 1a ). Very few foci were obtained with H-Ras alone and no foci at all were seen in the mock-transfected MEF. As expected, the co-transfection of the cyclin D2 in combination with an activated Ras gave some foci. It has been shown that cyclin D2 is able to transform primary REF in co-expression with an activated Ras (Kerkhoff and Ziff, 1995) . In that study, the oncogenic activity of cyclin D2 and H-Ras was much lower than the combination of c-Myc and H-Ras (Kerkhoff and Ziff, 1995) . However, when the MEF were co-transfected with an activated Ras and a truncated cyclin D2 expression vector, they presented a large number of foci at a density comparable to that obtained with H-Ras þ c-Myc (Table 1 ). The density of foci induced with the truncated cyclin D2 was much higher than that obtained with the full-length cyclin D2 suggesting that the truncated cyclin D2 is a more potent inducer of transformation. Also, the size of each foci was larger with the truncated cyclin D2. Similar transformation results were obtained with the human truncated cyclin D2 (results not shown). In contrast, the combination of the normal and the truncated cyclins D2 did not produce foci (results not shown).
MEF transfected with the truncated cyclin D2 and activated Ras were also treated with G418 for selection of stable transfectants. The colonies showing a transformed phenotype were selected and replated. These cells were dependent on the presence of serum for their proliferation and showed no contact inhibition and continued to proliferate even when confluency was reached (Figure 1b ). These cells were also morphologically different from the primary MEF as they were rod shaped and highly refractile. An important number of cells presenting multinucleation were also observed ( Figure 1b, lower panel) . Similar results were obtained with the combination of cyclin D2 and activated Ras stable transfectants (not shown; Kerkhoff and Ziff, 1995) . The majority of the truncated cyclin D2 and H-Ras stable transfectants were attached very weakly to the plates and only stable transfectants expressing low level of the truncated cyclin D2 were obtained (not shown). It is possible that high levels of expression of the truncated cyclin D2 in transformed MEF interfere with cell adhesion. This property was also observed in the cyclin D2 transformed REF (Kerkhoff and Ziff, 1995) . (Denicourt et al., 2002) . Interestingly, these ESTs were isolated from human brain tumor cDNA libraries. Also, in mouse, the truncated cyclin D2 is mainly expressed in the brain and ovaries (Denicourt et al., 2002) . To assess if the truncated cyclin D2 expression could be detected in primary brain tumors, we screened the RNA from a panel of different types of brain tumors by semi-quantitative RT-PCR. Compared to normal brain tissue, an increased expression of the truncated human cyclin D2 was observed in certain tumor types (Figure 2 ). Oligodendrogliomas, gliomas and glioblastomas multiforme (GBM) showed several fold increase in expression. In contrast, the expression levels in meningiomas, schwannomas and ependymomas remained as in normal brain tissue. The variation of expression observed in the GBMs could be due to some difference in the degree of malignancy in each sample or different form of tumor. GBMs can be classified as primary or secondary and there are evidences that primary and secondary glioblastomas are distinct diseases that evolve through distinct genetic pathways and may require different therapeutic approaches (Watanabe et al., 1996) . The expression of the normal cyclin D2 was also measured. No correlations were found between the expression levels of the two cyclins in the tumors nor between the expression levels of the full-length cyclin D2 and the different tumor types.
Truncated cyclin D2 displays a unique cytoplasmic localization To determine the subcellular localization of both the human and mouse truncated cyclin D2, we generated constructs containing, respectively, the truncated and the full-length cyclin D2 coding sequences fused to the EGFP or Myc epitope at the N-terminus. A mouse cyclin D2 mutant (D2D157-289) was generated by the deletion of amino acids 157-289 (Figure 3a) . The constructs were transfected into NIH/3T3 cells and the , GBM (glioblastoma multiforme), glio (mixed glioma), oligo (oligodendroglioma), epen (ependymoma), schw (schwannoma), men (meningioma). Hypoxanthine-guanine phosphoribosyltransferase (HPRT) was used as a control for the integrity of RNA samples. The fold increase indicates the relative level of the truncated human cyclin D2 amplification product over the HPRT internal control after normalization to the control sample (normal brain).
Characterization of mouse and human truncated cyclin D2 C Denicourt et al localization of the proteins was examined by fluorescence confocal microscopy. As shown in Figure 3b , EGFP alone shows a diffused generalized localization. EGFP-cyclin D2 protein was localized to the nucleus as expected. The mouse truncated cyclin D2, on the contrary, localizes only to cytoplasmic region. The mutant D2D157-289 who only differs from the D2Trc in the last 20 amino acids of the C-terminal end is observed in the nucleus. The human homolog also shows the same cellular distribution (Figure 3b ). Markers of the early and late endosomes (Rab 5a and Rab7) as well as a marker of the Golgi complex (BODIPY-Tr ceramids) did not show significant co-localization with the EGFP-truncated cyclin D2 (not shown). Treatment of transfected cells with leptomycin B revealed that the truncated cyclin D2 was not imported to the nucleus (Supplementary data). Cells transfected with Myctagged truncated cyclin D2 construct followed by immunocytochemistry with a Myc epitope antibody showed the same cytoplasmic distribution suggesting that the fused EGFP moiety does not alter the localization of the fusion protein (not shown). These three constructs were fused to the C-terminus of enhanced GFP using the pEGFP-C2 vector (mD2, mD2Trc, mD2D157-289). Similar constructions were made with the human normal (hD2) and truncated (hD2Trc) cyclin D2. The resulting constructs were transfected into NIH/3T3 cells, and the cells were examined by confocal microscopy.
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Truncated cyclin D2 retains the ability to interact with CDK4 in NIH/3T3 fibroblasts and forms an inactive complex In fibroblasts, CDK4 appears to be the most prominent partner of cyclin D2 (Matsushime et al., 1992; Xiong et al., 1992) . To test whether the truncated cyclin D2 can also interact with CDK4, NIH/3T3 fibroblasts were transfected with the Myc-tagged truncated and fulllength cyclin D2 (positive interaction control) constructs. Cell lysates were immunoprecipitated with an anti-CDK4 antibody. Western blot analysis with an anti-Myc epitope antibody showed that both cyclin D2 and truncated cyclin D2 could be co-immunoprecipitated in complex with CDK4 ( Figure 4a ). To evaluate if the truncated cyclin D2 is able to form an active complex with CDK4 or CDK6, we performed immunoprecipitation kinase assays using pRb C-terminus protein as a substrate. Myc-tagged cyclin D2 and truncated cyclin D2 constructs were transfected in NIH/3T3 cells and assayed for kinase activity after immunoprecipitation with Myc epitope antibody. Interestingly, we were not able to detect any activity above background for the truncated cyclin D2 (Figure 4b ). This suggests that the truncated cyclin D2 may not form complex with CDK under physiologic conditions or that the D2Trc-CDK4 complex that we detected may have activity toward another substrate. Because phosphorylation of CDK4 by CAK (CDK-activating kinase) is required for the activation of the assembled complex prior to the phosphorylation of pRb , we verified if the assembled D2Trc-CDK4 complex was phosphorylated by CAK. Myc-tagged cyclin D2 and D2Trc constructs were transfected in NIH/3T3 cells, isolated by immunoprecipitation with Myc epitope antibodies, and the immunoprecipitates were suspended in a kinase reaction buffer containing recombinant CAK (CDK7/cyclin H/MAT1) and [g 32 P]ATP. CDK4 associated with full-length cyclin D2 was efficiently phosphorylated by CAK, but the CDK4 associated to D2Trc was a very poor substrate (Figure 4c , upper panel). The inability of CAK to phosphorylate the CDK4-D2Trc complex is not due to a decreased association of CDK4 with D2Trc compared to the full-length cyclin D2 since equivalent amounts of CDK4 were assembled with the two cyclin proteins, as confirmed by blotting of the D2 immunoprecipitates with anti-CDK4 antibodies (Figure 4c, lower panel) . Moreover, in vitro kinase assay using the total cellular lysate as substrate was also performed and no significant phosphorylation from the D2Trc-CDK4 complex was observed (results not shown).
Expression of the truncated cyclin D2 in 32Dcl3 cells
In the hematopoietic cell line 32Dcl3, cyclin D2 is expressed in proliferating cells and its expression is dependent on interleukin-3 (IL-3). The expression declines rapidly in the absence of this growth factor (Ando et al., 1993) . To examine if the mouse truncated cyclin D2 presents the same profile of expression in this cell line, we analysed its expression in the presence and absence of IL-3. To arrest the cells in G 0 /G 1 , IL-3 was removed from the culture medium for 16 h. After, IL-3 was reintroduced in the medium to induce re-entry in the cell cycle. Samples of cells were collected at different time points and the expression of the cyclin D2 transcripts was analysed by northern blot. Figure 5a shows that the truncated cyclin D2 transcript declined rapidly in the absence of IL-3. When the IL-3-deprived cells were retreated back with IL-3, the 1.1 kb transcript was rapidly induced within 3 h. We also observed the same kinetic for the cyclin D2 6.5 kb transcript. The presence of the proteins was also analysed and the profiles of both the 17 kDa truncated and 32 kDa cyclin D2 proteins coincide with the observed induction of the mRNAs (Figure 5b) . These results suggests that the induction of the truncated cyclin D2 synthesis is controlled in the same fashion as the induction of the cyclin D2 protein, both expression being dependent on the presence of mitogenic factors.
Discussion
The truncated cyclin D2 was initially identified as a proto-oncogene that becomes activated upon retroviral insertion of the Graffi murine leukemia virus (Denicourt et al., 2002) . The results presented in this study also support the notion that the truncated cyclin D2 may play an important role in tumorigenesis. Indeed, we have shown that ectopic expression of the truncated cyclin D2, with an activated Ras, is able to induce a transformed phenotype to primary MEF. Moreover, the truncated cyclin D2 seems to be a more potent oncogene than the full-length cyclin D2 since the number of foci was much more important and comparable to that observed with the co-expression of c-Myc and activated Ras (Figure 1a) .
Cells derived from transformed foci after selection for the expression of the truncated cyclin D2 showed a high percentage of multinucleation, which is a characteristic of abnormal mitosis. These cells also presented loss of contact inhibition and grew as aggregates under subconfluent conditions suggesting that the ability of the truncated cyclin D2 to transform primary MEF may be due to alterations in cell adhesion (Figure 1b) . It was suggested that primary REF transformed by both activated Ras and full-length cyclin D2 possibly presented an altered expression of cell adhesion proteins since these cells attached very weakly to tissue culture plate and that this property necessitated their passage on collagen-coated plates (Kerkhoff and Ziff, 1995) . We have subcloned cell lines from individual foci of primary MEF and found that the cyclin D2 was poorly expressed. This is probably due to a selection against the establishment of transformed cell lines expressing high levels of the truncated cyclin D2. It is also possible that the high expression of the truncated cyclin D2 completely inhibits the adhesion of these cells. Consistent to our observations, rodent fibroblasts were found to have a strong selection against the establishment of cell lines that overexpress D-type cyclins (Quelle et al., 1993) . Integrin-mediated cell adhesion to the extracellular matrix is required for normal cell growth. It was shown that integrin signaling through focal adhesion kinase (FAK) plays a role in the regulation of the cell cycle progression by regulating the expression and activities of D-type cyclins (Assoian, 1997; Schwartz and Assoian, 2001 ). Roovers et al. (1999) have demonstrated that integrin-mediated cell adhesion is required for sustained ERK activation and induction of cyclin Lysates were prepared and subjected to immune precipitation using anti-Myc antibody. Precipitates were tested for in vitro kinase activity using glutathione S-transferase (GST)-Rb C 0 -terminus as substrate. Kinase reactions were analysed by SDS-PAGE followed by exposure of the gel on X-ray film (top panel). The gel was stained with Coomassie Brilliant Blue to visualize the substrate (GST-Rb) in each lane. Whole-cell lysates corresponding to each lane were analysed by immunoblot with anti-CDK4 and c-Myc antibody. (c) In vitro CAK phosphorylation of cyclin D2-CDK4 complexes. NIH/3T3 cell lysates containing CDK4 assembled with either Myc-cyclin D2 or Myc-D2Trc were precipitated with anti-Myc antibodies. Suspended immune complexes were used as substrates for recombinant CAK (CDK7/cyclin H/MAT1 produced in Sf21 cells), and 32 P-labeled complexes were denaturated and separated on polyacrylamide gels. The position of phosphorylated CDK4 is indicated on the left. Autoradiographic exposure time was 3 h (top panel). A portion of each cell lysate used in the CAK assay was precipitated with anti-Myc antibodies, separated on gel, blotted to PVDF membrane, probed with anti-CDK4 antibodies and visualized by enhanced chemiluminescence.
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C Denicourt et al D1 expression by growth factors. Also, ectopic overexpression of cyclin D1 induced anchorage-independent cell cycle progression of NIH/3T3 and Rat1 cells (Schulze et al., 1996; Zhu et al., 1996; Resnitzky, 1997) . These observations suggest that the truncated cyclin D2 is able to influence cellular adhesion. We also showed that the truncated cyclin D2 is expressed in a subset of primary brain tumors (oligodendrogliomas, mixed gliomas and glioblastomas multiforme) supporting again its role in tumorigenesis. It is interesting to note that the truncated cyclin D2 is abundant in the most aggressive brain tumor types. This overexpression does not seem to be correlated with the expression of the normal cyclin D2 (data not shown) but could be related with the degree of malignancy of these specific tumors. Buschges et al. (1999) also reported that the expression of normal cyclin D2 was not statistically significant between different tumor grades. We have already shown that the truncated cyclin D2 is present in the brain of normal mouse (Denicourt et al., 2002) .
We have shown that the truncated cyclin D2 localizes to a distinct cytoplasmic substructure in NIH/3T3 cells. D-types cyclins are known to accumulate in the cell nucleus during G 1 phase and disappear from the nuclei of cells undergoing DNA synthesis (Baldin et al., 1993) .
However, in our study, the truncated cyclin D2 was never observed in the cell nucleus of NIH/3T3 cells grown at different density. This was confirmed by leptomycin B treatment of cells transfected with an EGFP-truncated cyclin D2 construct (Supplementary data). It was shown that a cyclin D1 T156A mutant, which retains its ability to interact with CDK4, localizes uniquely to the cytoplasm of NIH/3T3 cells (Diehl and Sherr, 1997) . On the cyclin D2 protein, the T156 residue of cyclin D1 corresponds to T154. This residue is not conserved on the truncated cyclin D2 and this could explain its cytoplasmic localization. This observation is also supported by the nuclear localization of mutant D2D157-289 who still retains the T154 residue. It is interesting to note that mutant D2D157-289 that contains the first 156 amino acids of the normal cyclin D2 remains to the nucleus albeit the D2Trc is cytoplasmic. This indicates that the last 20 amino acids are responsible of the localization.
We have also demonstrated that the truncated cyclin D2 can interact with CDK4 when expressed ectopically in NIH/3T3 cells. The cyclins present a globular structure containing two sequential 90 amino acid repeats, known as the cyclin folds, each consisting of five super imposable a-helical bundles (Jeffrey et al., 1995; Kim et al., 1996; Russo et al., 1996; Andersen et al., 1997) . The two cyclin folds are connected via a short linker peptide of 10-15 amino acids. The first cyclin fold corresponds to what is defined as the cyclin box that makes contact with the interacting CDK. The second repeat on the cyclin does not contribute to the cyclin-CDK interface. The truncated cyclin D2 contains an almost intact cyclin box that could be responsible and sufficient for the interaction with CDK4. We examined if the truncated cyclin D2-CDK4 complex was catalytically active. It appears that the complex was unable to phosphorylate recombinant pRb protein in vitro (Figure 4b ). This lack of kinase activity is due to the inability of CAK to recognize and phosphorylate the D2Trc-CDK4 complex, which thus remains catalytically inactive (Figure 4c ). Cyclin D binding must induce a conformational change in the structure of CDK4 to make it available for phosphorylation. The fact that CAK could not phosphorylate CDK4 when complexed to the D2Trc suggests that the truncated form could not induce the conformational change but instead give rise to abortive complexes that are no longer recognized by CAK. The integrity of Thr-156 on cyclin D1 is required for CAK activity on the CDK4-cyclin complex (Diehl and Sherr, 1997) . The loss of Thr-154 on the D2Trc could be responsible for the inability of the CDK4 complex to be phosphorylated. Interestingly, a splice variant of cyclin D1 (cyclin D1b) harboring a different C 0 -terminus and lacking T286 was found to be a potent nuclear oncogene compared to the normal cyclin D1 (Lu et al., 2003) . This isoform has retained its ability to bind CDK4, but was unable to catalyse efficiently pRb phosphorylation and inactivation (Solomon et al., 2003) . This suggests that critical residues in the C-terminus of cyclin D proteins are important for substrate specificity. Despite its inability to phosphorylate Rb, Characterization of mouse and human truncated cyclin D2 C Denicourt et al the truncated cyclin D2 isoform demonstrated enhanced transforming activity compared with cyclin D2. The ability of the truncated cyclin D2 to promote cellular transformation is probably attributed to its constitutively cytoplasmic localization. Truncated cyclin D2 could sequester p27 (a cyclin D/CDK inhibitor) in the cytoplasm where it is degraded by the cytoplasmic ubiquitin ligase complex KPC, this step being essential for the progression of the cell cycle into S phase (Susaki et al., 2007 ). An upregulated cell cycle caused by the presence of the truncated cyclin D2 in the cytoplasm could be the cause of the enhanced transformation in presence of an activated Ras.
Expression of D-type cyclins is dependent on continuous mitogenic stimulation. In the hematopoietic cell line 32Dcl3, cyclin D2 is expressed in proliferating cells and this expression is dependent on the presence of IL-3. It was also shown in the same cell line that the expression and the protein levels of cyclin D2 declined rapidly upon withdrawal of IL-3 (Ando et al., 1993) . To investigate if the expression of the truncated cyclin D2 was also regulated in the same fashion in 32Dcl3 cells, we have reproduced some of the experiments by Ando et al. (1993) . Our results show that the truncated cyclin D2 expression and protein stability are dependent on the presence of mitogenic stimuli (IL-3) as already shown for the cyclin D2. This suggests that the expression of both transcripts (6.5 and 1.1 kb) of the cyclin D2 gene is controlled via the same regulatory elements, which are activated by growth factors. Indeed, the two transcripts most likely depend on the same promoter as they share the same 5 0 end and the first two exons (Denicourt et al., 2002) . Site-specific phosphorylation by GSK-3B of cyclins D1 and D2 on a single threonine residue (T286) is critical for maintaining their rapid turnover rates throughout the cell cycle and also upon mitogen signaling withdrawal (Diehl and Sherr, 1997; Diehl et al., 1998) . Although the truncated cyclin D2 does not harbor this T286 residue, our results showed that the protein level declined rapidly in the absence of IL-3. Also, we have demonstrated that the stability of the truncated cyclin D2 was dependent on proteasomal degradation (data not shown). It is possible that the turnover of the truncated cyclin D2 is dependent on the phosphorylation of another residue.
Taken together, these data demonstrate the activity of the truncated cyclin D2 in cellular transformation and a role in tumor formation. Because of its cytoplasmic localization, we propose that the truncated cyclin D2 may contribute to transformation by sequestering p27 in the cytoplasm, causing its degradation and, therefore, upregulating the cell cycle. It will, therefore, be important to identify the protein partners of this truncated cyclin D2.
Materials and methods

Cell lines, cell culture conditions and transfections
The 32Dcl3 diploid, non-leukemic, IL-3-dependent murine myeloid cell line (Greenberger et al., 1983) was obtained from Alan Friedman (Johns Hopkins University, Baltimore, MD, USA). These cells were maintained in RPMI 1640 medium (GIBCO, Burlington, ON, Canada) supplemented with 10% of heat-inactivated fetal calf serum (GIBCO) and 10% of WEHI-3B cells conditioned medium (WEHI-CM) as a source of IL-3. NIH/3T3 murine fibroblasts (ATCC, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium (GIBCO) supplemented with 10% of calf serum (GIBCO). All transfections were made with Polyfect regent (QIAGEN, Mississauga, ON, Canada) according to the manufacturer's protocol.
Mouse embryo fibroblasts transformation assay Primary fibroblasts were isolated from 15 days BALB/c mouse embryos. The cells were transfected with 4 mg of the pCMVD2Trc construct or the pCMV-D2 construct made by cloning the complete coding sequence of the truncated cyclin D2 or cyclin D2 obtained by PCR. The fragments were cloned in the pRcCMV vector (Invitrogen, Burlington, ON, Canada). The human truncated cyclin D2, obtained by PCR, and normal cyclin D2, Image clone ID: 4133621 (ATCC), were cloned in the pCMV5 vector. The cells were also transfected with 4 mg of the RAS EJ 6.6 construct (Tabin et al., 1982) and the pSV2-Myc construct. Transfections were made with Polyfect (QIAGEN) according to the manufacturer's instructions.
Primary human brain tumors
Samples of primary human brain tumors were obtained from The Arthur and Sonia Labatt Brain Tumour Research Center (Toronto, Canada).
RNA extraction and northern blot analysis
Total RNA from frozen human brain tumor tissue or 32Dcl3 cells was extracted with the TRIzol reagent (Invitrogen) according to the manufacturer's instructions.
Reverse transcription-PCR Total RNA (2 mg) was reverse transcribed into cDNA by using an oligo-dT primer (10 mM), dNTP mix (5 mM each dNTP), 10 Â reverse transcription buffer (500 mM Tris-HCl pH 8.3, 250 mM KCl, 50 mM MgCl 2 and 50 mM DTT), 10 U RNase inhibitor (GE Healthcare, Baie d'Urfe, Quebec, Canada) and 4 U of Omniscript Reverse Transcriptase (QIAGEN). The mix was incubated at 37 1C for 60 min. PCR was performed in 100 ml with 5 ml of the cDNA template, 0.2 mM dNTP, 2 mM MgCl 2 , 0.25 mM of each primer and 2.5 U of Taq DNA polymerase. The cycling conditions were 94 1C for 3 min, followed by 94 1C for 30 s, 60 1C for 30 s and 72 1C for 1 min for 25 cycles and a final extension at 72 1C for 10 min. Hypoxanthine-guanine phosphoribosyltransferase (HPRT) primers were used as an internal control under the same conditions. The primer sequences were as follows: normal cyclin D2, cyc1 (5 0 -GGCTGGGGTCCCGACTCCGAAG-3 0 ) and cyc2 (5 0 -GCAGCTCAGTCAGGGCATCACA-3 0 ), truncated cyclin D2, cyc1 (5 0 -GGCTGGGGTCCCGACTCCGA AG-3 0 ) and tcyc (5 0 -TGGCCAGGGGAAAGCGGGAATC-3 0 ). The HPRT primers were HPS1 (5 0 -GTGATGAAGGAGATG GGAGGCC-3 0 ) and SPH1 (5 0 -CTTCGTGGGGTCCTTTTC ACC-3 0 ). The resulting products were separated on a 1% agarose gel and the individual bands were quantified using the volume Rect tool from the Quantity one 4.4.0 software (Bio-Rad, Mississauga, ON, Canada).
Immunoprecipitation and immunoblotting
NIH/3T3 cells (1 Â 10 6 per 100 cm dish) transfected with the Myc-tagged truncated cyclin D2 (Myc-D2Trc) and
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Myc-tagged full-length cyclin D2 (Myc-D2) constructs were lysed 24 h after transfections in immunoprecipitation buffer (IP buffer) containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P-40 and complete protease inhibitor cocktail (Roche, Laval, Quebec, Canada) and sonicated on ice (Fisher cell dismembrator, 80% microtip power 10 s). Lysates were clarified by centrifugation at 10 000 g for 5 min. The supernatants were precipitated for 4 h at 4 1C with protein A-Sepharose beads (GE Healthcare) alone or precoated with saturating amounts of the anti-CDK4 antibody (Santa Cruz sc-601, Santa Cruz, CA, USA). The proteins immunoprecipitated on beads were washed five times with 1 ml of IP buffer. The beads were resuspended in 2 Â loading buffer (30% glycerol, 4% SDS, 160 mM Tris-HCl (pH 6.8), 10% B-mercaptoethanol and 0.02% bromophenol blue) and boiled for 10 min at 95 1C. Immunoprecipitated samples were separated on 12% SDS-PAGE and electrophoretically transferred to Immobilon-P PVDF membranes (Millipore, Billerica, MA, USA). For immunoblotting analysis, proteins were extracted in RIPA buffer and the protein concentration in the different extracts was measured using the Bio-Rad protein assay. Equal amounts of lysate proteins (30-80 mg) were diluted in 2 Â sample buffer (30% glycerol, 4% SDS, 160 mM Tris-HCl, pH 6.8, 10% b-mercaptoethanol and 0.02% bromophenol blue) and boiled for 3 min. Protein were separated on 12% SDS-PAGE and electrophoretically transferred to Immobilon-P PVDF membranes (Millipore). Membranes were blocked in PBS containing 0.2% Tween-20 and 4% skimmed milk powder (PBS-Tween-milk) for 1 h at room temperature. The antibodies were diluted in PBS-Tween-milk at the following dilutions: anti-truncated cyclin D2 peptide antibody (1:100) (Denicourt et al., 2002) , the anti-cyclin D2 (1:1000) (Cell Signaling, Danvers, MA, USA), the anti-Myc epitope antibody (1:5000) (Santa Cruz) or the anti-GAPDH antibody (1:300) (Chemicon, Temecula, CA, USA). The blots were incubated for 1 h at room temperature, washed in PBS-Tween and further incubated for 1 h with either anti-rabbit or antimouse IgG-peroxidase (BD Pharmingen, Mississauga, ON, Canada). The immune complexes were revealed using the ECL plus chemiluminescence regents (GE Healthcare).
Kinase assay NIH 3T3 cells were transfected with Myc-tagged cyclin D2 and truncated cyclin D2 using Lipofectamine 2000 (Invitrogen). Twenty-four hours after transfection, cells were lysed in buffer containing 50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 0.1% Tween 20, 1 mM dithiothreitol, 25 mM ATP and protease inhibitors. Lysates were precleared with protein G-Sepharose beads (Zymed, Burlington, ON, Canada) on a rotating wheel at 4 1C for 1 h. Two micrograms of anti-Myc epitope (9E10 SantaCruz) antibodies was used for immunoprecipitation. Kinase reactions were performed in 10 mM MgCl 2 and 50 mM HEPES (pH 7.2) with 2 mg of bacterially isolated glutathione S-transferase (GST)-Rb C 0 -terminus, 50 mM cold ATP and 10 mCi of [g- CAK activation assay NIH 3T3 cells were transfected with Myc-tagged cyclin D2 and truncated cyclin D2 using Lipofectamine 2000 (Invitrogen). Twenty-four hours after transfection, cells were lysed and immunoprecipitated as described above. The immunoprecipitates were washed three times with IP buffer and then three times with CAK buffer (80 mM b-glycerophosphate (pH 7.3), 15 mM MgCl 2 , 20mM EGTA and 5 mM dithiothreitol) . The beads were resuspended in 50 ml of CAK buffer containing protease, phosphatase inhibitors and 1.4 mg of recombinant CDK7-cyclin H-MAT1 complex (Upstate, Charlottesville, VA, USA). After addition of 40 mCi of [g-32 P] ATP in the presence of 50 mM ATP, the suspensions were incubated at 30 1C for 30 min. The precipitates were washed six times in Tween 20 lysis buffer (50 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 1 mM dithiothreitol, 0.1% Tween 20 and 10% glycerol), followed by denaturation by boiling in electrophoresis sample buffer for 5 min. Phosphorylated products were separated on denaturing polyacrylamide gels and visualized by autoradiography.
IL-3 starvation, stimulation and cell cycle analysis of 32Dcl3 cells IL-3 starvation was performed by washing the cells twice with PBS and reseeding them in culture medium without WEHI-CM for 16 h. After the IL-3 starvation, the cells were centrifuged and reseeded in culture medium containing WEHI-CM. Samples of cells were collected at different time points after IL-3 stimulation for northern and western blot analyses.
Immunofluorescence NIH/3T3 cells were seeded on coverslips 16 h prior to transfection. The cells were fixed 8-24 h after transfection in 4% paraformaldehyde for 10 min and permeabilized in 0.2% Triton X-100. Fixed cells were washed in PBS, and then blocked in 10% normal goat serum for 1 h at room temperature. Immunostaining was subsequently performed with an anti-Myc epitope antibody (Santa Cruz) (1:50) for 1 h at 25 1C. The cells were then incubated with Cy3-conjugated anti-mouse IgG (Jackson Immunoresearch, West Grove, PA, USA) for 1 h at 25 1C. The cells were washed extensively, mounted and imaged using a Zeiss Axioskop fluorescence microscope.
Construction of GFP fusion protein expression vectors
The cyclin D2 and the truncated cyclin D2 coding sequences for both the human and mouse were PCR amplified and cloned into in pEGFP-C2 vector (BD Biosciences Clontech, Mississauga, ON, Canada). The constructs were transfected in NIH/3T3 cells with QIAGEN Polyfect transfection reagent as recommended by the supplier. Cells were plated on Permanox Plastic Chamber Slide System (Fisher Scientific, Ottawa, ON, Canada) . Twenty-four hours later, cells were visualized by confocal microscopy. For control, cells were transfected with pEGFP-C2 vector alone.
Construction of cyclin D2 mutant
The cyclin D2 mutant (D2D157-289) was produced by a PCR-based site-directed mutagenesis method as previously described by Fisher and Pei (1997) . The following oligonucleotide primers were used: 5 0 -PTTAGTGAGGGGTGACTGCG GCCAGG-3 0 (stop codon is underlined) and 5 0 -GCCACCGC GGTGGAGCGCCAATTC-3 0 . Cyclin D2 cloned into pBluescript II KS þ was used as PCR template.
